目的 探讨固本咳喘胶囊联合丙酸倍氯米松气雾剂治疗支气管哮喘的临床疗效。方法 选取2017年12月-2018年12月武汉市第六医院收治的90例支气管哮喘患者作为研究对象，按照随机数字表法将患者分为对照组和治疗组，每组各45例。对照组给予丙酸倍氯米松气雾剂，1揿/次，3次/d；治疗组在对照组的基础上口服固本咳喘胶囊，3粒/次，3次/d。两组患者均连续治疗3个月。观察两组的临床疗效，比较两组的肺功能、T淋巴细胞亚群、炎性因子水平。结果 治疗后，对照组和治疗组的总有效率分别为84.44%、97.78%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者第一秒用力呼气容积（FEV1）、最大呼气峰流速（PEF）、用力呼气肺活量（FVC）均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组患者肺功能指标均明显高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者的CD3⁺、CD4⁺、CD4⁺/CD8⁺均明显提高，CD8⁺明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组患者T淋巴细胞亚群明显优于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者超敏C反应蛋白（hs-CRP）、肿瘤细胞坏死因子-α（TNF-α）、白细胞介素-8（IL-8）水平均明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组患者的炎性因子水平明显低于对照组，两组比较差异有统计学意义（P<0.05）。结论 固本咳喘胶囊联合丙酸倍氯米松气雾剂治疗支气管哮喘具有较好的临床疗效，能改善患者的肺功能，调节T淋巴细胞亚群和炎性因子水平，具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Guben Kechuan Capsules combined with Beclometasone Dipropionate Aerosol in treatment of bronchial asthma. Methods Patients (90 cases) with bronchial asthma in Affiliated Hospital of Jianghan University from December 2017 to December 2018 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were given Beclometasone Dipropionate Aerosol, 1 press/time, three times daily. Patients in the treatment group were po administered with Guben Kechuan Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and pulmonary function, T lymphocyte subsets, and inflammatory factor levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 84.44% and 97.78%, respectively, and there was difference between two groups (P<0.05). After treatment, FEV1, PEF, and FVC in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the pulmonary function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the T lymphocyte subsets in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of hs-CRP, TNF-α, and IL-8 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the inflammatory factor levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Guben Kechuan Capsules combined with Beclometasone Dipropionate Aerosol has clinical curative effect in treatment of bronchial asthma, can improve the lung function, regulate the level of T-lymphocyte subsets and inflammatory factors, which has a certain clinical application value.